Under the Surface: New Perspectives in Lupus with TLR7/8 Inhibition - Report from EULAR 2026

Dr. Victoria Werth provides an expert analysis of the EULAR 2026 session exploring the role of Toll-like receptor 7 and 8 (TLR7/8) inhibition in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). This recap looks beneath the surface at the underlying pathogenic mechanisms of the disease, highlighting the latest clinical data and new therapeutic perspectives on how targeting the TLR7/8 pathway could transform future treatment strategies and patient outcomes.Video: https://medicaldigest.org/scientific-contents/interview:under-surface-new-perspectives-lupus-tlr78-inhibition